Posted by Michael Wonder on 24 May 2017
European Commission grants marketing authorisation for Zebinix (eslicarbazepine acetate) as once daily monotherapy in adults with newly diagnosed partial-onset epilepsy
23 May 2017 - Bial and Eisai today announce that the EMA has approved Zebinix (eslicarbazepine acetate) for use as a once-daily monotherapy to treat adults with newly-diagnosed partial-onset epilepsy.
Eslicarbazepine acetate is already indicated in Europe as adjunctive therapy in adults, adolescents and children aged above six years, with partial-onset seizures with or without secondary generalisation.
